Saturday, September 23, 2023
Saturday, September 23, 2023

Theken Companies Acquires VisionAir Solutions

VisionAir Solutions creates patient-specific airway stents with its 3D-design platform. VisionAir 3D Patient-Specific Stents provide improved stent life, increased time between interventions, and reduced complications for an improved patient quality of life.

VisionAir 3D Stents are personalized by pulmonologists using innovative cloud software (VisionAir 3D Stent Architect). With this unique software a physician simply uploads a patient’s scans and receives a personalized silicone stent within days that fits the patient’s specific anatomy near to perfect. This allows physicians to tailor a 3D Stent to each patient’s unique anatomy to reduce complications caused by poorly-fitting stock silicone stents. Instead of an average stock stent life of 60 days, these patient-specific stents have an average life of years, although the VisionAir stent is clinically approved by the FDA for one year. To see how simple the process is, view the video here

VisionAir stents have broad indications for the treatment of symptomatic central airway obstruction (CAO) in mature individuals that are 22 years of age or older. 3D Stents may be implanted in any location in the airway that a physician can reach with a rigid bronchoscope for implantation. This means that the 3D Stent is unique in that it can be designed to fit carinas distal to the main carina, while current traditional silicone Y-stents have stock diameters, angles, and lengths specifically designed for only the main carina.

Randy Theken, Founder of Theken Companies, said of the acquisition, “I was truly overwhelmed by the technology created by the VisionAir team at Cleveland Clinic. The VisionAir 3D Patient-Specific Stents provide significantly improved stent life and an improved patient quality of life. This is exciting not only for the pulmonary field, but for the potential to apply this technology to other medical devices.”

Thomas Gildea, MD, FCCP, FACP, of Cleveland Clinic and Inventor and Head of the Clinical Advisory Team at VisionAir Solutions, stated, “We are excited to collaborate with Randy Theken and the new VisionAir team. They continue to share our vision of bringing innovative technology to as many patients as possible.” Cleveland Clinic has an equity interest in VisionAir and is entitled to royalty payments and other commercialization revenues from the company for technology developed at Cleveland Clinic. VisionAir is the developer and manufacturer of the stents. Dr. Gildea and others at Cleveland Clinic are inventors and are entitled to royalty payments and other commercialization revenues from the company in accordance with Cleveland Clinic policy.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Summus Raises $19.5 Million

Fundraise supports market expansion with Summus emerging as the premier clinical platform to share and access high quality specialty expertise across the continuum of care — serving employers, payers, health systems and physician groups.

Thirona Raises €7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine

With this financing, Thirona plans to accelerate the adoption of its break-through innovations for precision medicine.

Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes

The trial will evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence, notes Levee Medical.

Innovac Therapeutics Completes $18 million Series Pre-A Financing To Fund the Development of Its lead Programs and Manufacturing Capabilities

The funding represents a strong endorsement of Innovac's technology, mission and vision from a range of industry Investors.

TherageniX and University of Nottingham Awarded £995K Innovate UK Grant to Develop Powdered Gene Therapy for Bone Regeneration

Dr Anandkumar Nandakumar, CEO of TherageniX, commented: “Our mission is to advance treatments in repairing tissue damage and we are grateful for the support from Innovate UK at this early stage. This grant is a testament to the potential of TherageniX’s novel approach to tissue regeneration and will enable us to make great strides in manufacturing our powdered gene therapy.

By using this website you agree to accept Medical Device News Magazine Privacy Policy